XML 44 R23.htm IDEA: XBRL DOCUMENT v3.22.2
OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS (Tables)
6 Months Ended
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Inventory
Components of selected captions in the consolidated condensed balance sheets consisted of the following:
June 30, 2022December 31, 2021
Inventories
Raw materials$140.9 $132.8 
Work in process165.9 164.3 
Finished products433.2 429.6 
$740.0 $726.7 
Schedule of Accounts Payable and Accrued Liabilities
June 30, 2022December 31, 2021
Accrued and other liabilities 
Employee compensation and withholdings$256.0 $319.7 
Taxes payable94.1 30.6 
Property, payroll, and other taxes55.8 68.9 
Research and development accruals57.0 58.2 
Accrued rebates89.6 77.0 
Fair value of derivatives2.0 3.9 
Accrued marketing expenses16.5 20.1 
Legal and insurance (a)
83.2 79.1 
Accrued relocation costs26.5 26.2 
Accrued professional services11.1 11.9 
Accrued realignment reserves13.2 19.1 
Other accrued liabilities78.3 87.6 
$783.3 $802.3 
_______________________________________
(a)     On July 12, 2020, the Company reached an agreement with Abbott Laboratories and its direct and indirect subsidiaries to, among other things, settle all outstanding patent disputes between the companies in cases related to transcatheter mitral and tricuspid repair products. As of June 30, 2022, $54.4 million was accrued in "Accrued and other liabilities" and $167.2 million was accrued in "Litigation settlement accrual" on the consolidated condensed balance sheet.
Schedule of Cash Flow, Supplemental Disclosures
Supplemental Cash Flow Information
(in millions)
Six Months Ended
June 30,
20222021
Cash paid during the year for:
Income taxes$173.0 $66.6 
Amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases
$14.5 $16.3 
Non-cash investing and financing transactions:  
Right-of-use assets obtained in exchange for new lease liabilities$10.6 $5.4 
Capital expenditures accruals$24.6 $25.1 
Conversion of notes receivable to equity investment$— $21.5 
Schedule of Cash and Cash Equivalents
Cash, Cash Equivalents, and Restricted Cash
(in millions)
June 30, 2022December 31, 2021
Cash and cash equivalents$1,198.1 $862.8 
Restricted cash included in other current assets1.8 1.5 
Restricted cash included in other assets3.0 3.1 
Total cash, cash equivalents, and restricted cash$1,202.9 $867.4 
Schedule of Restricted Cash
Cash, Cash Equivalents, and Restricted Cash
(in millions)
June 30, 2022December 31, 2021
Cash and cash equivalents$1,198.1 $862.8 
Restricted cash included in other current assets1.8 1.5 
Restricted cash included in other assets3.0 3.1 
Total cash, cash equivalents, and restricted cash$1,202.9 $867.4